GGrantIndex
← Leaderboards

Boris Decourt

Banner Health

$2,811,849
Attributed
$6,247,689
Total exposure
3
Grants
1
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.4M · FY201523
$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23

Funding mix

By agency

NIH$6,247,689 · 3

By mechanism

R01$5,713,874 · 2
K01$533,815 · 1

Top collaborators

Most similar at Banner Health

Same institution · by research overlap

Others in their field

Top investigators on “Alzheimer&Apos

Research focus

Alzheimer&AposCognitionFda ApprovedPharmaceutical PreparationsLenalidomideThalidomideNeuropathologyNeuroinflammationClinical TrialsImpaired CognitionDesignInflammatoryDoseTau ProteinsS DiseaseAmyloid Beta-ProteinBrainInflammationAnalogClinical ResearchAdverse EventTnf GeneAnti-Inflammatory AgentsInflammatory Marker

Grant awards (15)

MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients$701,731
R01 · FY2023 · AG
Repurposing Siponimod for Alzheimer's Disease$687,290
R01 · FY2023 · AG
Repurposing Siponimod for Alzheimer's Disease$688,670
R01 · FY2022 · AG
MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients$663,871
R01 · FY2022 · AG
Repurposing Siponimod for Alzheimer's Disease$731,856
R01 · FY2021 · AG
Assessment of lenalidomide to treat Alzheimer's disease$639,729
R01 · FY2021 · AG
Administrative Supplement for 1R01AG059008-01: Requested for investigational drug expenses$402,379
R01 · FY2020 · AG
Assessment of lenalidomide to treat Alzheimer's disease$702,328
R01 · FY2019 · AG
Pre-clinical testing of lenalidomide as pleiotropic therapeutics of Alzheimer's disease$101,264
K01 · FY2019 · AG · contact PI
Pre-clinical testing of lenalidomide as pleiotropic therapeutics of Alzheimer's disease$5,499
K01 · FY2019 · AG · contact PI
Assessment of lenalidomide to treat Alzheimer's disease$496,020
R01 · FY2018 · AG
Pre-clinical testing of lenalidomide as pleiotropic therapeutics of Alzheimer's disease$106,763
K01 · FY2018 · AG · contact PI
Pre-clinical testing of lenalidomide as pleiotropic therapeutics of Alzheimer's disease$106,763
K01 · FY2017 · AG · contact PI
Pre-clinical testing of lenalidomide as pleiotropic therapeutics of Alzheimer's disease$106,763
K01 · FY2016 · AG · contact PI
Pre-clinical testing of lenalidomide as pleiotropic therapeutics of Alzheimer's disease$106,763
K01 · FY2015 · AG · contact PI